Sign Up to like & get
recommendations!
1
Published in 2018 at "Atherosclerosis"
DOI: 10.1016/j.atherosclerosis.2018.07.017
Abstract: BACKGROUND AND AIMS Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, significantly reduces low-density lipoprotein cholesterol (LDL-C). We evaluated the efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus (T2DM)…
read more here.
Keywords:
efficacy safety;
without mdl;
alirocumab;
efficacy ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Atherosclerosis"
DOI: 10.1016/j.atherosclerosis.2021.06.913
Abstract: BACKGROUND AND AIMS Trials of the fully human monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) alirocumab in hypercholesterolemia demonstrated substantial low-density lipoprotein cholesterol (LDL-C) lowering, reduction in cardiovascular (CV) events and outcomes, and…
read more here.
Keywords:
risk;
neurocognitive function;
treatment;
alirocumab ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2016.11.046
Abstract: BACKGROUND PCSK9 inhibition with alirocumab significantly reduced LDL-C levels in trials of up to 78weeks' duration in patients with heterozygous familial hypercholesterolemia (HeFH). We report results from 3years of an ongoing open-label treatment extension (NCT01576484)…
read more here.
Keywords:
week;
treatment;
ldl;
alirocumab ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2019.10.057
Abstract: BACKGROUND Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). OBJECTIVES A pre-specified analysis of the placebo-controlled ODYSSEY Outcomes trial in patients…
read more here.
Keywords:
risk;
mace;
acute coronary;
alirocumab ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-020-0991-1
Abstract: Background Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardiovascular risk. Non-HDL-C and apolipoprotein B (ApoB) are…
read more here.
Keywords:
non hdl;
hdl;
mean difference;
usual care ... See more keywords